Suchergebnisse - "Darunavir/administration & dosage"

Once-daily dolutegravir versus darunavir plus ritonavir for treatment-naive adults with HIV-1 infection (FLAMINGO): 96 week results from a randomised, open-label, phase 3b study.

Autoren: Molina, J.M. Clotet, B. van Lunzen, J. et al.

Weitere Verfasser: Molina, J.M. Clotet, B. van Lunzen, J. et al.

Schlagwörter: Adolescent, Adult, Analysis of Variance, Anti-HIV Agents/administration & dosage, Darunavir/administration & dosage, Drug Administration Schedule, Drug Resistance, Viral/drug effects, Drug Therapy, Combination, Female, HIV Infections/drug therapy, HIV Infections/immunology, HIV-1, Heterocyclic Compounds, 3-Ring/administration & dosage, Humans, Male, Ritonavir/administration & dosage, Treatment Outcome, Viral Load/drug effects

Relation: The Lancet HIV; https://iris.unil.ch/handle/iris/124404; serval:BIB_56AFF9065EE0; 000363792300008

Verfügbarkeit: https://iris.unil.ch/handle/iris/124404
https://doi.org/10.1016/S2352-3018(15)00027-2

Once‐daily darunavir/ritonavir 400/100 mg in triple therapy: efficacy and penetration in seminal compartment in ANRS‐165 DARULIGHT study

Autoren: Lê, Minh Chaix, Marie‐laure Raffi, François et al.

Weitere Verfasser: Lê, Minh Chaix, Marie‐laure Raffi, François et al.

Quelle: British Journal of Clinical Pharmacology. 85:277-280

Schlagwörter: 0301 basic medicine, unbound total, [SDV.IMM] Life Sciences [q-bio]/Immunology, [SDV]Life Sciences [q-bio], MESH: HIV Infections / drug therapy, MESH: Darunavir / pharmacokinetics, MESH: Dose-Response Relationship, darunavir, MESH: Drug Administration Schedule, MESH: HIV-1 / drug effects, seminal and blood plasma, MESH: HIV Infections / blood, MESH: HIV-1 / isolation & purification, MESH: Drug Therapy, 03 medical and health sciences, 0302 clinical medicine, MESH: HIV Infections / virology, MESH: Drug Combinations, [SDV.MP.VIR] Life Sciences [q-bio]/Microbiology and Parasitology/Virology, MESH: Adult, MESH: Darunavir / administration & dosage, MESH: HIV-1 / genetics, 3. Good health, [SDV] Life Sciences [q-bio], MESH: HIV Protease Inhibitors / pharmacokinetics, dose reduction, [SDV.SP.PHARMA] Life Sciences [q-bio]/Pharmaceutical sciences/Pharmacology, [SDV.MP.VIR]Life Sciences [q-bio]/Microbiology and Parasitology/Virology, [SDV.SP.PHARMA]Life Sciences [q-bio]/Pharmaceutical sciences/Pharmacology, [SDV.IMM]Life Sciences [q-bio]/Immunology, MESH: HIV Protease Inhibitors / administration & dosage, Drug, Combination / methods

Zugangs-URL: https://bpspubs.onlinelibrary.wiley.com/doi/pdfdirect/10.1111/bcp.13796
https://bpspubs.onlinelibrary.wiley.com/doi/abs/10.1111/bcp.13796
http://europepmc.org/abstract/MED/30421447
https://bpspubs.onlinelibrary.wiley.com/doi/pdf/10.1111/bcp.13796
https://www.ncbi.nlm.nih.gov/pubmed/30421447
https://ut3-toulouseinp.hal.science/hal-03639183v1
https://doi.org/10.1111/bcp.13796

Long‐term clinical experience with darunavir (2007–2015) in a large cohort of HIV‐infected patients in Spain

Autoren: Pernas, Berta Grandal, Marta Tabernilla, Andrés et al.

Weitere Verfasser: Pernas, Berta Grandal, Marta Tabernilla, Andrés et al.

Quelle: RUC. Repositorio da Universidade da Coruña
instname

Schlagwörter: 0301 basic medicine, Adult, Male, Efficacy, Anti-HIV Agents, HIV Infections/drug therapy, Long Term Adverse Effects, HIV Infections, HIV Protease Inhibitors/administration & dosage, Drug Administration Schedule, Lopinavir, Anti-HIV Agents/administration & dosage, Ritonavir/administration & dosage, 03 medical and health sciences, 0302 clinical medicine, Humans, Lopinavir/adverse effects, RNA, Viral/blood, Darunavir, Retrospective Studies, 0303 health sciences, Sulfonamides, Ritonavir, Sulfonamides/adverse effects, HIV Protease Inhibitors, Viral Load, HIV infection, Viral Load/drug effects, 3. Good health, CD4 Lymphocyte Count, HIV-1/drug effects, Spain, Darunavir/administration & dosage, HIV-1, young adult, RNA, Viral, Drug Therapy, Combination, Female, Safety

Dateibeschreibung: application/pdf

Zugangs-URL: https://ruc.udc.es/dspace/bitstream/2183/18373/2/Pernas_Long.pdf
https://pubmed.ncbi.nlm.nih.gov/27218208
http://hdl.handle.net/2183/18373
http://onlinelibrary.wiley.com/doi/10.1002/jmv.24585/abstract
http://europepmc.org/abstract/MED/27218208
https://ruc.udc.es/dspace/handle/2183/18373
https://ruc.udc.es/dspace/bitstream/2183/18373/2/Pernas_Long.pdf
https://hdl.handle.net/2183/18373
https://biblio.vub.ac.be/vubir/longterm-clinical-experience-with-darunavir-20072015-in-a-large-cohort-of-hivinfected-patients-in-spain(b5b097fd-31bf-48e3-a7e6-637a98d2735f).html
https://hdl.handle.net/20.500.14017/b5b097fd-31bf-48e3-a7e6-637a98d2735f
https://doi.org/10.1002/jmv.24585

Fixed dose darunavir boosted with cobicistat combined with emtricitabine and tenofovir alafenamide fumarate

Autoren: Cevik, Muge Orkin, Chloe

Quelle: Cevik , M & Orkin , C 2018 , ' Fixed dose darunavir boosted with cobicistat combined with emtricitabine and tenofovir alafenamide fumarate ' , Current opinion in HIV and AIDS , vol. 13 , no. 4 , pp. 315-319 . https://doi.org/10.1097/COH.0000000000000465

Schlagwörter: Anti-HIV Agents/administration & dosage, Clinical trials, Phase II as topic, Phase III as topic, Darunavir/administration & dosage, Drug therapy, combination, Emtricitabine/administration & dosage, HIV Infections/drug therapy, Humans, Randomized controlled trials as topic, Tenofovir/administration & dosage

Verfügbarkeit: https://research-portal.st-andrews.ac.uk/en/publications/0be88d35-6eb5-40a1-b0f4-4d00151f1ced
https://doi.org/10.1097/COH.0000000000000465